霍乱疫苗使用与结直肠癌患者死亡风险降低相关:一项基于人群的研究
该研究基于瑞典癌症登记库,纳入2005年7月至2012年12月确诊的结直肠癌患者,通过处方登记库检索霍乱疫苗使用情况,采用Cox回归计算死亡风险比。结果显示,诊断后使用霍乱疫苗的175例患者与倾向评分匹配对照相比,结直肠癌死亡风险(HR 0.53,95%CI 0.29-0.99)和总死亡风险(HR 0.59,95%CI 0.37-0.94)均降低。
要点
- 诊断后使用霍乱疫苗的结直肠癌患者结直肠癌死亡风险降低(HR 0.53,95%CI 0.29-0.99)。
- 诊断后使用霍乱疫苗的结直肠癌患者总死亡风险降低(HR 0.59,95%CI 0.37-0.94)。
- 死亡风险降低在不同年龄、肿瘤分期和性别中大体一致。
核心结论
- 在基于人群的研究中,结直肠癌诊断后使用霍乱疫苗与结直肠癌死亡风险和总死亡风险降低相关。
研究设计与样本
- 基于人群的研究,从瑞典癌症登记库识别2005年7月至2012年12月确诊的结直肠癌患者,并链接瑞典处方药物登记库检索霍乱疫苗使用情况。
- 共175例结直肠癌患者在癌症诊断后获得霍乱疫苗处方,采用Cox回归分析计算结直肠癌死亡和总死亡的风险比,并与倾向评分匹配对照比较。
主要发现
- 与倾向评分匹配对照相比,校正混杂因素后,接受霍乱疫苗的结直肠癌患者结直肠癌死亡风险降低(HR 0.53;95%CI 0.29-0.99)。
- 与倾向评分匹配对照相比,校正混杂因素后,接受霍乱疫苗的结直肠癌患者总死亡风险降低(HR 0.59;95%CI 0.37-0.94)。
- 霍乱疫苗接种相关的死亡风险降低在患者诊断时年龄、肿瘤分期或性别方面大体一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Cholera toxin can act as a modulator of the immune response with anti-inflammatory effects; it reduces development of colon polyps in mouse models of colorectal cancer (CRC). We performed a population-based study to determine whether, in patients with a diagnosis of CRC, subsequent administration of the cholera vaccine (killed Vibrio cholerae O1 whole cells and recombinant cholera toxin B subunit) affects mortality. METHODS: We identified patients from the Swedish Cancer Register who were diagnosed with CRC from July 2005 through December 2012. These patients were linked to the Swedish Prescribed Drug Register to retrieve cholera vaccine use. We used Cox regression analysis to calculate the hazard ratio (HR) of death from CRC and overall mortality in patients with post-diagnostic use of cholera vaccine compared with matched controls. RESULTS: A total of 175 patients were diagnosed with CRC and given a prescription for the cholera vaccine after their cancer diagnosis. Compared with propensity score-matched controls and adjusted for confounding factors, patients with CRC who received the cholera vaccine had a decreased risk of death from CRC (HR, 0.53; 95% CI, 0.29-0.99) and a decreased risk of death overall (HR, 0.59; 95% CI, 0.37-0.94). The decrease in mortality with cholera vaccination was largely observed, irrespective of patient age or tumor stage at diagnosis or sex. CONCLUSIONS: In a population-based study, we associated administration of the cholera vaccine after CRC diagnosis with decreased risk of death from CRC and overall mortality.
引用
- Ji J, Sundquist J, Sundquist K, et al. Cholera Vaccine Use Is Associated With a Reduced Risk of Death in Patients With Colorectal Cancer: A Population-Based Study. Gastroenterology. 2017. PMID: 28923497. doi:10.1053/j.gastro.2017.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。